Apyx Medical Corp (APYX)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-09
$3.050.00%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-09
Broken: Primary pillar broken — Cash flow from operations turns positive: OCF -0.6M vs >0 target.
Apyx raised revenue guidance to about $59.5 million for 2026. Revenue grew 11.6% expected next year. Cash flow losses are shrinking, showing progress. Management aims to improve profits and cash flow.
Apyx is still losing money and cash flow is negative. Revenue fell in early 2026. Profit remains weak and may not improve soon.
The price is about 26% below our fair value near $6. Analysts expect about 12% revenue growth. We see progress but risks remain.
Breaks if: Operating income remains below negative $911,000 over next year
Breaks if: Cash flow from operations remains negative over next year
Total revenue falls below $59 million in FY2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity with a focus on the healthcare sector. The current thesis state has weakened due to recent financial performance and an earnings miss, leading to increased uncertainty.
The market seems to assume a justified valuation for APYX, as it is considered cheap compared to peers. However, there is a notable expectations gap, indicating that the market may be cautious about future performance.
Management is on track to increase revenue guidance for FY2026, with a 22% year-over-year growth in Q2 2026. However, the overall financial performance has been weak, and the company remains loss-making, which adds to the risk.
The long-term thesis hinges on management's ability to meet revenue guidance and successfully expand product capabilities. Additionally, external factors such as sector performance and economic conditions will significantly impact APYX's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The reason to own APYX has diminished. Recent financial performance fell to the 1st percentile of its sector. The latest earnings report showed a miss, which added to concerns.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, APYX's prospects depend on effective execution of its growth strategies and the broader healthcare sector's performance. Not investment advice.